Free tool
FAERS Monitor: Vectibix
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125147 or its brand name (Vectibix, Panitumumab). Reports on generic versions are filed under their own applications.
Reports
16,106
Serious
14,116
88% of reports
Hospitalization
5,471
Death reported
2,738
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- rash1,979
- diarrhoea1,649
- dermatitis acneiform1,069
- death1,060
- neutropenia963
- skin toxicity934
- nausea863
- colorectal cancer metastatic861
- hypomagnesaemia849
- disease progression749
- neuropathy peripheral749
- off label use743
- fatigue719
- dry skin717
- vomiting663
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 3 |
| 2006 | 26 |
| 2007 | 315 |
| 2008 | 326 |
| 2009 | 334 |
| 2010 | 359 |
| 2011 | 601 |
| 2012 | 524 |
| 2013 | 489 |
| 2014 | 625 |
| 2015 | 709 |
| 2016 | 962 |
| 2017 | 965 |
| 2018 | 1,176 |
| 2019 | 1,241 |
| 2020 | 1,015 |
| 2021 | 891 |
| 2022 | 956 |
| 2023 | 1,169 |
| 2024 | 1,050 |
| 2025 | 948 |
| 2026 | 1,422 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,038,053 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| colorectal cancer metastaticSignal | 861 | 744.3 | 685.5 | 406,710 |
| dermatitis acneiformSignal | 1,069 | 278.0 | 260.8 | 243,149 |
| skin toxicitySignal | 934 | 258.3 | 241.2 | 199,713 |
| hypomagnesaemiaSignal | 849 | 84.7 | 79.2 | 65,912 |
| neuropathy peripheralSignal | 749 | 10.4 | 9.7 | 6,300 |
| neutropeniaSignal | 963 | 9.3 | 8.8 | 7,128 |
| disease progressionSignal | 749 | 8.3 | 7.7 | 4,808 |
| dry skinSignal | 717 | 7.0 | 6.6 | 3,718 |
| rashSignal | 1,979 | 6.0 | 5.7 | 8,282 |
| diarrhoeaSignal | 1,649 | 3.3 | 3.2 | 2,783 |
| vomiting | 663 | 1.8 | 1.7 | 260 |
| death | 1,060 | 1.6 | 1.5 | 253 |
| nausea | 863 | 1.4 | 1.3 | 113 |
| fatigue | 719 | 1.2 | 1.1 | 26 |
| off label use | 743 | 1.1 | 1.0 | 8 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.